Bacterial vesicles hold immense potential in various biomedical fields, including vaccines, antimicrobial agents, drug delivery systems, and cancer immunotherapy. Among these, outer membrane vesicles (OMVs) produced by Gram-negative bacteria are among the most extensively studied. While the exact mechanism of OMV production remains unclear, numerous environmental factors have been shown to influence both the yield and composition of OMVs. In this study, we investigated the effect of three different antimicrobial families on OMV production by E. coli. Interestingly, antimicrobials within the same family did not provide the same effects on OMV yield, suggesting that OMV production may not directly correlate with the antimicrobial mechanism of action.

OMVs have demonstrated tumor-inhibitory activity in multiple mouse tumor models. However, their potential toxicity poses a significant challenge, as OMVs have been shown to cause mortality in mice. To address this limitation, we developed bacterial-engineered vesicles (BEVs) as a safer alternative to OMVs. Proteomic analysis revealed that BEVs contained fewer outer membrane proteins compared to OMVs. In vitro assays, BEVs effectively repolarized pro-tumor macrophages (M2) to the anti-tumor phenotype (M1) and promoted dendritic cell maturation. Additionally, BEVs were shown to serve as a versatile platform for antigen peptide display, with the displayed peptides not interfering with BEVs' inherent immunomodulatory activity.

We further evaluated the anti-tumor efficacy of BEVs in a B16F10 melanoma model. The intravenous administration of BEVs significantly inhibited tumor growth and elicited robust immune responses. Flow cytometry analysis of spleen and lymph node samples from BEV-treated mice revealed an elevated M1/M2 macrophage ratio and an increased population of CD8+ T cells. To explore combination therapies, we generated cancer cell-derived vesicles (PD-1 CEVs) using PD-1-transfected B16F10 cells. Interestingly, while BEVs alone inhibited tumor growth effectively, the co-administration of BEVs and PD-1 CEVs resulted in comparable tumor suppression but attenuated immune responses. However, a significant decrease in regulatory T cell percentages was monitored among all vesicle-treated groups compared to the PBS control group. This unexpected immune modulation warrants further investigation to understand the mechanisms underlying PD-1 CEV-mediated immune suppression.

Zoom link: